本文關(guān)鍵詞：sFas和sFasL在乳腺癌新輔助化療過程中的臨床意義　出處：《浙江大學(xué)》2015年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 乳腺癌 sFas sFasL 新輔助化療 化學(xué)標(biāo)記物

【摘要】：目的：通過檢測乳腺癌患者新輔助前、后及術(shù)后血清sFas和sFasL水平,對比其變化趨勢,初步探討sFas來源及臨床指導(dǎo)意義,試圖為乳腺癌臨床診療方案的制定提供更簡便、更客觀的臨床依據(jù)。 方法：1.前瞻性篩選患者17名,條件：浸潤性導(dǎo)管癌、符合前輔助化療適應(yīng)癥、年齡30-65歲,女性；對比組為15名健康女性,條件：對已排除高血壓、糖尿病等慢性疾病,同時排除有血液疾病病史或其他惡性腫瘤的患者。2.采用酶聯(lián)免疫吸附法(ELISA)檢測乳腺癌患者及健康女性血清中sfas和sFasL含量。3.采用GraphPad.Prism.v5.0for windows統(tǒng)計軟件進(jìn)行分析。 結(jié)果：1.sFas在新輔助化療前乳腺癌患者血清中含量低(39.58±17.38),與正常人群(20.56±6.807)相比無顯著統(tǒng)計學(xué)差異(p=0.2122)；在新輔助化療后患者血清中濃度增高(302.8±72.86),與新輔助化療前及正常對照組均存在顯著統(tǒng)計學(xué)差異(p0.05)；患者術(shù)后血清中濃度較新輔助后(即術(shù)前)無顯著統(tǒng)計學(xué)差異(p=0.4259)。2.對于雌激素受體陽性乳腺癌患者,新輔助化療有效組(CR+PR)的sFas血清含量(前20.60±9.974、后175.4±59.15)較無效患者(SD+PD)兩組中患者sFas血清含量(前19.82-9.143、后511.6±381.6)明顯增高,存在明顯差異(p0.05)。3.sFasL在新輔助前后、術(shù)后、正常對照組之間均無統(tǒng)計學(xué)差異(p=0.1160、p=0.2530、p=0.5845)。 結(jié)論：1.患者血清中sFas在新輔助化療后顯著上升。2.sFas可以對于ER陽性乳腺癌患者,通過觀察其血清濃度變化,早期預(yù)測新輔助化療療效。3.sFasL在患者血清中治療前后均無明顯變化。
[Abstract]:Objective: to study the origin and clinical significance of sFas and sFasL in patients with breast cancer by detecting the levels of serum sFas and sFasL before, after and after neoadjuvant operation. This paper attempts to provide a more simple and objective clinical basis for the clinical diagnosis and treatment of breast cancer. Methods 17 patients with invasive ductal carcinoma were selected prospectively. The patients were in accordance with the indications of preadjuvant chemotherapy, aged 30-65 years, female; The control group consisted of 15 healthy women. The condition was that hypertension, diabetes and other chronic diseases were excluded. Exclusion of patients with a history of blood disease or other malignant neoplasms .2.Enzyme-linked immunosorbent assay (Elisa). The levels of sfas and sFasL in serum of breast cancer patients and healthy women were measured. 3. GraphPad.Prism.v5.0for was used. Windows statistical software was used to analyze. Results 1. The serum level of SFAS in breast cancer patients before neoadjuvant chemotherapy was 39.58 鹵17.38). There was no significant difference between 0.2122 and 20.56 鹵6.807 in normal population. After neoadjuvant chemotherapy, the serum concentration increased by 302.8 鹵72.86, which was significantly different from that before neoadjuvant chemotherapy and normal control group (P 0.05). There was no significant difference in serum concentration between the patients after operation and that after neoadjuvant (i.e., preoperative). For breast cancer patients with estrogen receptor positive, there was no significant difference. The serum level of sFas in neo-adjuvant chemotherapy group was 20.60 鹵9.974. The serum levels of sFas in the latter 175.4 鹵59.15 were significantly higher than those in the ineffective group (19.82-9.143, 511.6 鹵381.6). There was significant difference between the two groups before and after the neo-adjuvant operation, and there was no significant difference between the normal control group and the normal control group before and after neoadjuvant operation. (P = 0.5845). Conclusion: 1. The serum levels of sFas in patients with ER positive breast cancer were significantly increased after neoadjuvant chemotherapy. 2. SFAS could be used to observe the changes of serum concentration in patients with ER positive breast cancer. Early prediction of neoadjuvant chemotherapeutic efficacy. 3. SFasL had no significant change in serum before and after treatment.
【學(xué)位授予單位】：浙江大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R737.9

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 ;Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro[J];World Journal of Gastroenterology;2008年15期

，

本文編號：1441235